These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15826289)

  • 21. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis.
    Heintz BH; Matzke GR; Dager WE
    Pharmacotherapy; 2009 May; 29(5):562-77. PubMed ID: 19397464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy.
    Kiser TH; Fish DN; Aquilante CL; Rower JE; Wempe MF; MacLaren R; Teitelbaum I
    Crit Care; 2015 Feb; 19(1):32. PubMed ID: 25645660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent hemodialysis versus continuous renal replacement therapy for acute renal failure in the intensive care unit: an observational outcomes analysis.
    Rauf AA; Long KH; Gajic O; Anderson SS; Swaminathan L; Albright RC
    J Intensive Care Med; 2008; 23(3):195-203. PubMed ID: 18474503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous renal replacement therapy in sepsis and multisystem organ failure.
    Joannidis M
    Semin Dial; 2009; 22(2):160-4. PubMed ID: 19426421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous renal replacement therapy in the treatment of acute renal failure: critical assessment is required.
    Himmelfarb J
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):385-9. PubMed ID: 17699438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacokinetics of antibiotics in continuous renal replacement therapies (CRRT)].
    Morabito S; Pistolesi V; Maggiore U; Fiaccadori E; Pierucci A
    G Ital Nefrol; 2012; 29(4):425-44. PubMed ID: 22843155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
    Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug dosing during continuous renal replacement therapy.
    Churchwell MD; Mueller BA
    Semin Dial; 2009; 22(2):185-8. PubMed ID: 19426426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage.
    Böhler J; Donauer J; Keller F
    Kidney Int Suppl; 1999 Nov; (72):S24-8. PubMed ID: 10560800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of continuous renal replacement therapy on drug therapy.
    Susla GM
    Clin Pharmacol Ther; 2009 Nov; 86(5):562-5. PubMed ID: 19727069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to optimize drug delivery in renal replacement therapy.
    Awdishu L; Bouchard J
    Semin Dial; 2011; 24(2):176-82. PubMed ID: 21517984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modalities of continuous renal replacement therapy: technical and clinical considerations.
    Cerdá J; Ronco C
    Semin Dial; 2009; 22(2):114-22. PubMed ID: 19426413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complications of continuous renal replacement therapy.
    Finkel KW; Podoll AS
    Semin Dial; 2009; 22(2):155-9. PubMed ID: 19426420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
    Isla A; Maynar J; Sánchez-Izquierdo JA; Gascón AR; Arzuaga A; Corral E; Pedraz JL
    J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulation for continuous renal replacement therapy.
    Tolwani AJ; Wille KM
    Semin Dial; 2009; 22(2):141-5. PubMed ID: 19426417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey.
    RENAL Study Investigators
    Crit Care Resusc; 2008 Sep; 10(3):225-30. PubMed ID: 18798721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Common places on clinical management of acute renal failure].
    Martínez J; Martínez E; Herreros A
    Nefrologia; 2005; 25 Suppl 2():3-9. PubMed ID: 16050394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug dosing in continuous renal replacement therapy: general rules.
    Schetz M
    Curr Opin Crit Care; 2007 Dec; 13(6):645-51. PubMed ID: 17975384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy.
    Tillman J
    Nurs Crit Care; 2009; 14(4):191-9. PubMed ID: 19531037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial.
    Lins RL; Elseviers MM; Van der Niepen P; Hoste E; Malbrain ML; Damas P; Devriendt J;
    Nephrol Dial Transplant; 2009 Feb; 24(2):512-8. PubMed ID: 18854418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.